Stockscreener 앱 받기
151.48
0.34%
-0.52
시간 외 거래:
151.48
Aptargroup Inc 주식(ATR)의 최신 뉴스
Aptar CSP Launches cGMP-Compliant Manufacturing Facility in NJ - Contract Pharma
Aptar Reports Second Quarter 2024 Results - Seeking Alpha
AptarGroup, Inc. (NYSE:ATR) Q1 2025 Earnings Call Transcript - Insider Monkey
AptarGroup Inc (ATR) Q1 2025 Earnings Call Highlights: Navigating Currency Headwinds and Tax ... - Yahoo
AptarGroup Inc (ATR) Q1 2025 Earnings Call Highlights: Navigating Currency Headwinds and Tax ... By GuruFocus - Investing.com Canada
AptarGroup’s Q1 2025 Results: Sales Dip, Pharma Grows - TipRanks
Earnings call transcript: AptarGroup Q1 2025 sees modest EPS beat By Investing.com - Investing.com South Africa
AptarGroup’s Earnings Call: Growth Amid Challenges - TipRanks
Aptar (ATR) Reports Q1 Revenue Miss but Highlights Strong Segmen - GuruFocus
Earnings call transcript: AptarGroup Q1 2025 sees modest EPS beat - Investing.com
APTARGROUP, INC. SEC 10-Q Report - TradingView
AptarGroup (ATR) Surpasses Q1 EPS Expectations, Provides Optimis - GuruFocus
AptarGroup: Q1 Earnings Snapshot - MySA
Aptar Q1 2025 slides: Flat sales but improved margins amid segment variability By Investing.com - Investing.com South Africa
AptarGroup Inc (ATR) Q1 2025 Earnings: EPS of $1.17 Beats Estima - GuruFocus
Aptar (ATR) Positioned for Strong Performance with Resilient Mar - GuruFocus
Aptargroup Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aptar Reports First Quarter 2025 Results | ATR Stock News - GuruFocus
Aptar Q1 2025 slides: Flat sales but improved margins amid segment variability - Investing.com India
AptarGroup (ATR) Q1 Earnings Top Estimates - Yahoo Finance
Aptar Reports First Quarter 2025 Results - Aptar
AptarGroup Q1 Earnings, Revenue Fall - marketscreener.com
AptarGroup, Inc. Reports First Quarter 2025 Results - TradingView
Earnings Flash (ATR) APTARGROUP INC. Reports Q1 Adjusted EPS $1.20, vs. FactSet Est of $1.16 - marketscreener.com
AptarGroup Inc (ATR) Q1 2025 Earnings Report Preview: What to Lo - GuruFocus
Subdued Growth No Barrier To AptarGroup, Inc.'s (NYSE:ATR) Price - simplywall.st
Aptar Named One of America’s Climate Leaders by USA Today for Third Consecutive Year - Aptar
AptarGroup About To Put More Money In Your Pocket (ATR) - Nasdaq
Aptar Pharma Presents Webinar on GLP-1 Drug Development - Aptar
Aptar Reports Fourth Quarter and Annual 2024 Results - ADVFN
AptarGroup (ATR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo
Here’s Why Upslope Capital Management Exited its Stake in AptarGroup (ATR) - MSN
AptarGroup (ATR) Price Target Lowered by Raymond James Amid Cautious Outlook | ATR Stock News - GuruFocus
Aptar Declares Quarterly Dividend - BioSpace
AptarGroup Keeps Quarterly Dividend at $0.45 a Share, Payable May 22 to Holders of Record on May 1 - marketscreener.com
Aptar Declares Quarterly Dividend – April 2025 - Aptar
Aptar Declares Quarterly Dividend | ATR Stock News - GuruFocus
AptarGroup Sets $0.45 Quarterly Dividend: What the May Earnings Call Could Reveal - Stock Titan
Will AptarGroup (ATR) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Is AptarGroup, Inc.'s (NYSE:ATR) Recent Stock Performance Tethered To Its Strong Fundamentals? - simplywall.st
AptarGroup Launching Validation Study of SmartTrack Platform - marketscreener.com
AptarGroup (ATR) Launches Clinical Study for SmartTrack Platform Validation | ATR Stock News - GuruFocus
Aptar Receives Platinum Rating from EcoVadis for the Fifth Conse - GuruFocus
AptarGroup begins study for generic drug approval process - Investing.com Australia
AptarGroup begins study for generic drug approval process By Investing.com - Investing.com Canada
Aptar Announces Clinical Validation Study to Accelerate US FDA Approval of SmartTrack™ In-Vitro-in-Silico Platform for Pressurized Metered-Dose Inhalers - marketscreener.com
Aptar Receives Platinum Rating from EcoVadis for the Fifth Consecutive Year - GuruFocus
1.08%
자본화:
|
볼륨(24시간):